Developer docs
API playgroundTry for free, no card

Search company profiles

SSI Strategy

Full company profile

uuid0003psd

Namestring
SSI Strategy
Legal namestring
SSI Strategy LLC
Websiteurl
ssistrategy.com
Company typeenum
Private
Founded yearint
2011
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech consulting services, drug development advisory, regulatory affairs consulting, clinical development strategy, pharmacovigilance consulting
NAICS code3 codes
  • Management Consulting Services54161
  • Management, Scientific, and Technical Consulting Services5416
  • Other Scientific and Technical Consulting Services54169
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Life Sciences Consulting
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Strategic Consulting Services
TypeProfessional Services
Description

SSI Strategy generates revenue through fee-for-service consulting engagements with biotech clients. Services span the drug development lifecycle including strategic medical office, translational & clinical development, clinical operations, evidence & value, medical affairs, program management & governance, quality & compliance, regulatory affairs, safety & PV, and high-stakes FDA/EMA meetings. Revenue is project-based and retainer-oriented, reflecting a professional services model.

ssistrategy.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Custom consulting engagements — no standardized tiers publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

SSI Strategy operates on a bespoke, project-based consulting model. No pricing tiers, rate cards, or subscription plans are publicly disclosed. Clients contact the firm directly for proposals and statements of work.

ssistrategy.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SSI Strategy is a strategic consulting firm that embeds seasoned executives, clinicians, regulatory experts, and operators directly into biotech and biopharma organizations. It delivers multidisciplinary advisory services across the drug development lifecycle — from pre-clinical and translational strategy through clinical operations, regulatory affairs, evidence generation, medical affairs, safety/pharmacovigilance, quality and compliance, to high-stakes FDA/EMA meeting preparation and commercialization readiness.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • SSI Strategy has served over 280 biopharma companies across U.S. and European markets since 2010.
+3 more records
Product overview1 text field

SSI Strategy is a strategic consulting firm for biotech innovators offering multidisciplinary consulting services across the drug development lifecycle from preclinical through commercialization. The core offering consists of integrated consulting service modules including The Strategic Medical Office, Translational & Clinical Development, Clinical Operations, Evidence & Value, Medical Affairs, Program Management & Governance, Quality & Compliance, Regulatory Affairs, Safety & PV, and High-Stakes Meetings support. These services are delivered through bespoke teams of regulatory experts, clinicians, safety professionals, and business consultants embedded directly into client organizations. Supporting content platforms include The Emerging Biotech Leader Podcast and Regulatory: The Emerging C-Suite Leader Podcast. Advisory services include the Executive Advisory Network (connecting clients with active biotech leaders) and the NDA Advisory Board for regulatory strategy support.

Product and service13 records
1The Strategic Medical Office
CategoryStrategic Medical Consulting
Description

Strategic medical office consulting service ensuring scientific integrity and patient advocacy through strategic alignment and stakeholder engagement for biotech organizations.

2Translational & Clinical Development
CategoryClinical Development Consulting
Description

Clinical development consulting service that innovates life-changing therapies through patient-centric clinical development, transforming assets and organizations into clinical-stage entities.

3Clinical Operations
CategoryClinical Operations Consulting
Description

Clinical operations consulting service empowering sponsors with strategic leadership and operational excellence in clinical trial execution.

4Evidence & Value
CategoryEvidence & Health Economics Consulting
Description

Evidence and value consulting service unlocking therapy's full potential with strategic evidence generation, health economics, and real-world evidence for regulatory approval and payer acceptance.

5Medical Affairs
CategoryMedical Affairs Consulting
Description

Medical affairs consulting service transforming medical affairs into a strategic driver for success, supporting medical organization design and launch readiness.

6Program Management & Governance
CategoryProgram Management Consulting
Description

Program management and governance consulting navigating complexity with strategic oversight and cross-functional collaboration for drug development programs.

7Quality & Compliance
CategoryQuality & Compliance Consulting
Description

Quality and compliance consulting service accelerating success through strategic quality and compliance consulting, including inspection readiness and QMS gap assessments.

8Regulatory Affairs
CategoryRegulatory Affairs Consulting
Description

Regulatory affairs consulting service providing regulatory strategy and leadership for drug development, including NDA advisory board support and EU regulatory submissions.

9Safety & PV
CategoryPharmacovigilance Consulting
Description

Safety and pharmacovigilance consulting service safeguarding patient well-being through strategic risk management and operational excellence in pharmacovigilance.

10High-Stakes Meetings
CategoryRegulatory Meeting Preparation
Description

High-stakes meetings consulting service driving success in pivotal FDA and EMA interactions, helping clients prepare for critical regulatory meetings.

11Executive Advisory Network
CategoryExecutive Advisory Service
Description

Curated advisory network of active biotech and biopharma Board Members, CEOs, and CMOs providing independent, non-salaried strategic counsel to SSI clients at pivotal inflection points, including former executives from Novartis, Roche, Merck, and GSK.

12NDA Advisory Board
CategoryRegulatory Advisory Service
Description

Strategic advisory service providing regulatory expertise and guidance for NDA preparation and submission processes.

13Embedded Executive Services
CategoryEmbedded Consulting Model
Description

Bespoke embedded service model placing teams of regulatory experts, clinicians, safety professionals, and business consultants as an extension of client organizations, including Board Member, CEO, CMO, and Functional Leader placements.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Clinigen Group, a global pharmaceutical services company focused on improving patient access to medicines, entered into a definitive agreement to acquire SSI Strategy in September 2025. The acquisition combines SSI's strategic depth, established U.S. and European footprint, and pioneering partnership models with Clinigen's global operational reach in clinical trial supply, managed access, and commercialisation. The deal adds 200 employees (including 145 expert consultants) and a client base of over 280 biopharma companies to Clinigen's Lifecycle Services offering. The transaction was expected to close before end of 2025, subject to customary closing conditions. SSI continues to operate as SSI Strategy under current leadership (CEO Doug Locke) post-close.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-29
Description

SSI Strategy announced the acquisition of Fiore Healthcare Advisors, a long-term partner and life sciences consultancy, in June 2021. Fiore Healthcare Advisors had been scaled by founder Greg Fiore, MD (who co-founded SSI Strategy in 2011) to nearly $10 million in annual revenues before its acquisition. The deal brought additional pharmacovigilance and medical affairs expertise to SSI's service portfolio. Amit Patel, former President of Fiore Healthcare Advisors, joined SSI Strategy as SVP to lead the Pharmacovigilance Services Hub.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Trinity Partners
TypeDirect peer
Description

A life sciences-focused strategy consulting firm serving biotech and pharmaceutical clients across commercial, R&D, and medical affairs. Closely comparable to SSI in its biotech specialization, project-based delivery model, and therapeutic-area depth.

TypeDirect peer
Description

Biopharma strategy consulting firm focused on commercial strategy, market access, and evidence generation. Comparable to SSI's Evidence & Value and Medical Affairs service lines and its emerging/mid-stage biotech client base.

TypeBroad incumbent
Description

Global CRO and life sciences consulting powerhouse with deep R&D, real-world evidence, and strategic advisory capabilities. Competes with SSI for biotech consulting work and counts SSI's CFO Craig Ungaro among its former healthcare leadership.

TypeBroad incumbent
Description

Global consulting firm with a Life Sciences practice providing strategic and economic advice to biopharma and medtech clients. Overlaps with SSI on regulatory strategy, evidence generation, and commercial launch advisory.

TypeDirect peer
Description

Life sciences consulting firm specializing in medical affairs, evidence generation, HEOR, and value strategy. Direct overlap with SSI's Medical Affairs, Evidence & Value, and Strategic Medical Office offerings.

6Defined Health
TypeDirect peer
Description

Biotech strategy consulting firm advising emerging therapeutic companies on clinical development, regulatory, and commercial strategy. Directly comparable in client segment and strategic advisory focus.

TypeDirect peer
Description

Regulatory and FDA/EMA meeting preparation consultancy. Closely comparable to SSI's High-Stakes Meetings and Regulatory Affairs service modules, and counts SSI's SVP Laurie Smaldone Alsup among its alumni.

TypeDirect peer
Description

Regulatory affairs consultancy with deep NDA submission expertise and an advisory board offering. Directly comparable to SSI's NDA Advisory Board and Regulatory Affairs practices.

TypeDirect peer
Description

Biotech-focused consulting firm providing strategy, due diligence, and commercial advisory to emerging biotechs. Highly comparable to SSI's emerging-biotech focus and therapeutic-area expertise.

TypeBroad incumbent
Description

Large diversified professional services firm with a significant life sciences practice spanning R&D, regulatory, and clinical operations. Competes with SSI for biotech consulting engagements and counts SSI's SVP Leah Damesek among its alumni.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SSI Strategy

Life Sciences Consultingssistrategy.com

SSI Strategy firmographics

Firmographics
Name
SSI Strategy
Legal name
SSI Strategy LLC
Website
https://ssistrategy.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Where SSI Strategy is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices5 records

Markets served

SSI Strategy business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Strategic Consulting Services: SSI Strategy generates revenue through fee-for-service consulting engagements with biotech clients. Services span the drug development lifecycle including strategic medical office, translational & clinical development, clinical operations, evidence & value, medical affairs, program management & governance, quality & compliance, regulatory affairs, safety & PV, and high-stakes FDA/EMA meetings. Revenue is project-based and retainer-oriented, reflecting a professional services model.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom consulting engagements — no standardized tiers publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

SSI Strategy product offering

Product offering

Core offering

SSI Strategy is a strategic consulting firm that embeds seasoned executives, clinicians, regulatory experts, and operators directly into biotech and biopharma organizations. It delivers multidisciplinary advisory services across the drug development lifecycle — from pre-clinical and translational strategy through clinical operations, regulatory affairs, evidence generation, medical affairs, safety/pharmacovigilance, quality and compliance, to high-stakes FDA/EMA meeting preparation and commercialization readiness.

Product overview

SSI Strategy is a strategic consulting firm for biotech innovators offering multidisciplinary consulting services across the drug development lifecycle from preclinical through commercialization. The core offering consists of integrated consulting service modules including The Strategic Medical Office, Translational & Clinical Development, Clinical Operations, Evidence & Value, Medical Affairs, Program Management & Governance, Quality & Compliance, Regulatory Affairs, Safety & PV, and High-Stakes Meetings support. These services are delivered through bespoke teams of regulatory experts, clinicians, safety professionals, and business consultants embedded directly into client organizations. Supporting content platforms include The Emerging Biotech Leader Podcast and Regulatory: The Emerging C-Suite Leader Podcast. Advisory services include the Executive Advisory Network (connecting clients with active biotech leaders) and the NDA Advisory Board for regulatory strategy support.

Differentiator

Problem solved

Functional benefit

Products and services

  • The Strategic Medical Office Strategic medical office consulting service ensuring scientific integrity and patient advocacy through strategic alignment and stakeholder engagement for biotech organizations.
  • Translational & Clinical Development Clinical development consulting service that innovates life-changing therapies through patient-centric clinical development, transforming assets and organizations into clinical-stage entities.
  • Clinical Operations Clinical operations consulting service empowering sponsors with strategic leadership and operational excellence in clinical trial execution.
  • Evidence & Value Evidence and value consulting service unlocking therapy's full potential with strategic evidence generation, health economics, and real-world evidence for regulatory approval and payer acceptance.
  • Medical Affairs Medical affairs consulting service transforming medical affairs into a strategic driver for success, supporting medical organization design and launch readiness.
  • Program Management & Governance Program management and governance consulting navigating complexity with strategic oversight and cross-functional collaboration for drug development programs.
  • Quality & Compliance Quality and compliance consulting service accelerating success through strategic quality and compliance consulting, including inspection readiness and QMS gap assessments.
  • Regulatory Affairs Regulatory affairs consulting service providing regulatory strategy and leadership for drug development, including NDA advisory board support and EU regulatory submissions.
  • Safety & PV Safety and pharmacovigilance consulting service safeguarding patient well-being through strategic risk management and operational excellence in pharmacovigilance.
  • High-Stakes Meetings High-stakes meetings consulting service driving success in pivotal FDA and EMA interactions, helping clients prepare for critical regulatory meetings.
  • Executive Advisory Network Curated advisory network of active biotech and biopharma Board Members, CEOs, and CMOs providing independent, non-salaried strategic counsel to SSI clients at pivotal inflection points, including former executives from Novartis, Roche, Merck, and GSK.
  • NDA Advisory Board Strategic advisory service providing regulatory expertise and guidance for NDA preparation and submission processes.
  • Embedded Executive Services Bespoke embedded service model placing teams of regulatory experts, clinicians, safety professionals, and business consultants as an extension of client organizations, including Board Member, CEO, CMO, and Functional Leader placements.

Quantifiable outcome

  • SSI Strategy has served over 280 biopharma companies across U.S. and European markets since 2010.
  • +3 more outcomes

Companies that use SSI Strategy

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

SSI Strategy technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

SSI Strategy partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Clinigen GroupcoreStrategic or Co-development Partner · 29 September 2025Clinigen Group, a global pharmaceutical services company focused on improving patient access to medicines, entered into a definitive agreement to acquire SSI Strategy in September 2025. The acquisition combines SSI's strategic depth, established U.S. and European footprint, and pioneering partnership models with Clinigen's global operational reach in clinical trial supply, managed access, and commercialisation. The deal adds 200 employees (including 145 expert consultants) and a client base of over 280 biopharma companies to Clinigen's Lifecycle Services offering. The transaction was expected to close before end of 2025, subject to customary closing conditions. SSI continues to operate as SSI Strategy under current leadership (CEO Doug Locke) post-close.
  • Fiore Healthcare AdvisorscoreStrategic or Co-development Partner · 29 June 2021SSI Strategy announced the acquisition of Fiore Healthcare Advisors, a long-term partner and life sciences consultancy, in June 2021. Fiore Healthcare Advisors had been scaled by founder Greg Fiore, MD (who co-founded SSI Strategy in 2011) to nearly $10 million in annual revenues before its acquisition. The deal brought additional pharmacovigilance and medical affairs expertise to SSI's service portfolio. Amit Patel, former President of Fiore Healthcare Advisors, joined SSI Strategy as SVP to lead the Pharmacovigilance Services Hub.

Scale indicators7 records

Recent moves5 records

Expansion highlights6 records

SSI Strategy competitors and assessment

Company assessment

Direct peers

  • Trinity Partners: A life sciences-focused strategy consulting firm serving biotech and pharmaceutical clients across commercial, R&D, and medical affairs. Closely comparable to SSI in its biotech specialization, project-based delivery model, and therapeutic-area depth.
  • Putnam Associates: Biopharma strategy consulting firm focused on commercial strategy, market access, and evidence generation. Comparable to SSI's Evidence & Value and Medical Affairs service lines and its emerging/mid-stage biotech client base.
  • Lumanity: Life sciences consulting firm specializing in medical affairs, evidence generation, HEOR, and value strategy. Direct overlap with SSI's Medical Affairs, Evidence & Value, and Strategic Medical Office offerings.
  • Defined Health: Biotech strategy consulting firm advising emerging therapeutic companies on clinical development, regulatory, and commercial strategy. Directly comparable in client segment and strategic advisory focus.
  • PharmApprove: Regulatory and FDA/EMA meeting preparation consultancy. Closely comparable to SSI's High-Stakes Meetings and Regulatory Affairs service modules, and counts SSI's SVP Laurie Smaldone Alsup among its alumni.
  • NDA Group: Regulatory affairs consultancy with deep NDA submission expertise and an advisory board offering. Directly comparable to SSI's NDA Advisory Board and Regulatory Affairs practices.
  • Alacrita Consulting: Biotech-focused consulting firm providing strategy, due diligence, and commercial advisory to emerging biotechs. Highly comparable to SSI's emerging-biotech focus and therapeutic-area expertise.

Broad incumbents

  • IQVIA: Global CRO and life sciences consulting powerhouse with deep R&D, real-world evidence, and strategic advisory capabilities. Competes with SSI for biotech consulting work and counts SSI's CFO Craig Ungaro among its former healthcare leadership.
  • Charles River Associates: Global consulting firm with a Life Sciences practice providing strategic and economic advice to biopharma and medtech clients. Overlaps with SSI on regulatory strategy, evidence generation, and commercial launch advisory.
  • Huron Consulting Group: Large diversified professional services firm with a significant life sciences practice spanning R&D, regulatory, and clinical operations. Competes with SSI for biotech consulting engagements and counts SSI's SVP Leah Damesek among its alumni.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

SSI Strategy social profiles

Digital presence

SSI Strategy compliance and trust

Trust signal

Compliance1 record

SSI Strategy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SSI Strategy leadership team

Management profile

Number of profiles

Profiles9 records

SSI Strategy subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SSI Strategy funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SSI Strategy M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SSI Strategy

What does SSI Strategy do?

SSI Strategy is a strategic consulting firm that embeds seasoned executives, clinicians, regulatory experts, and operators directly into biotech and biopharma organizations. It delivers multidisciplinary advisory services across the drug development lifecycle — from pre-clinical and translational strategy through clinical operations, regulatory affairs, evidence generation, medical affairs, safety/pharmacovigilance, quality and compliance, to high-stakes FDA/EMA meeting preparation and commercialization readiness.

Is SSI Strategy a public or private company?

SSI Strategy is a private company. It is classified as private equity controlled and is currently operating.

When was SSI Strategy founded?

SSI Strategy was founded in 2011. It employs 101 to 250 people.

Where is SSI Strategy based?

SSI Strategy is headquartered in Parsippany, United States, in the North America region.

How does SSI Strategy make money?

One revenue line is on record: strategic Consulting Services.

Who are SSI Strategy's main competitors?

Direct peers on record are Trinity Partners, Putnam Associates, Lumanity, Defined Health, PharmApprove, NDA Group and Alacrita Consulting. Broad incumbents are IQVIA, Charles River Associates and Huron Consulting Group.

Does SSI Strategy have an API?

No public API is recorded for SSI Strategy.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AxiosScoop: Clinigen acquiring SSI Strategy for high-teens multipleTriton-backed Clinigen is acquiring biotech consultancy SSI Strategy at a high-teens EBITDA multiple, according to two sources familiar with the situation. The transaction highlights continued strong valuations for private equity-backed pharma services businesses. Financial terms of the deal were not disclosed.SsistrategySSI Strategy to Join Clinigen Group, Charting a Seamless Path from Clinical Strategy to Global CommercialisationClinigen Group announced a definitive agreement to acquire SSI Strategy, a strategic consulting partner to biotech innovators, in a deal expected to close before the end of 2025. The acquisition combines SSI's strategic consulting expertise and established U.S. and European footprint with Clinigen's global operational reach in clinical trial supply, managed access, and commercialisation. The deal adds 200 employees including 145 expert consultants, a client base of over 280 biopharma companies, and positions Clinigen in the $12-13 billion global market for pharmaceutical lifecycle services expected to grow nearly 10% annually through 2030.PharmiWeb.comClinigen to Acquire SSI Strategy, Charting a Seamless Path from Clinical Strategy to Global Commercialisation for Biotech InnovatorsClinigen, a global pharmaceutical services company, announced it has entered into a definitive agreement to acquire SSI Strategy, a strategic consulting partner serving biotech innovators, with the transaction expected to close before the end of the year. The acquisition adds 200 employees including 145 expert consultants, a client base of over 280 biopharma companies, and deep expertise across medical, clinical, and regulatory competencies spanning more than 15 therapeutic areas. The combined entity positions Clinigen to serve the $12-13 billion global pharmaceutical lifecycle services market, projected to grow at nearly 10% annually through 2030.ClinigengroupClinigen to Acquire SSI StrategyClinigen has entered into a definitive agreement to acquire SSI Strategy, a strategic consulting partner to biotech innovators, with the transaction expected to close before the end of 2025. The acquisition adds 200 employees, including 145 expert consultants spanning Medical, Clinical, and Regulatory competencies, along with a client base of over 280 biopharma companies across more than 15 therapeutic areas. The combined entity will target the $12-13 billion global market for pharmaceutical lifecycle services, projected to grow by nearly 10% annually through 2030.AxiosScoop: Amulet Capital exploring sale of SSI StrategyAmulet Capital is exploring a sale of SSI Strategy, a biotech consulting firm, according to four sources familiar with the situation. This would mark at least the fourth pharma services deal since last October, signaling continued consolidation activity in the sector. No further details about the potential transaction terms or timeline were disclosed.KoneksahealthKoneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical TrialsKoneksa and SSI Strategy announced an expanded partnership to accelerate the adoption of digital biomarkers in clinical trials. The collaboration integrates SSI's medical strategy division with Koneksa's digital biomarker platform, providing clients with combined scientific and technical expertise across all phases of drug development. This strategic move aims to streamline client relationships and enhance the efficiency of clinical research for life sciences companies.Business Wire BlogSSI Strategy and NDA Group Combine to Form Best-in-Class Global Life Sciences ConsultancySSI Strategy agreed to acquire NDA Group, a regulatory and drug development consultancy, to form an integrated provider of drug development and regulatory services. Financial terms were not disclosed. NDA will operate as a strategic business unit under SSI.FierceBiotechKoneksa links with SSI Strategy to advance digital biomarker servicesKoneksa partnered with SSI Strategy to expand its digital biomarker services in clinical trials, with SSI joining to help grow the medical division. The deal, undisclosed in financial terms, gives Koneksa access to SSI's Ph.D.s and physicians in drug development. The partnership responds to growing demand for in-house digital biomarker solutions.FinSMEsSSI Strategy Receives Investment from Amulet Capital PartnersSSI Strategy, a Parsippany, NJ-based Life Sciences consultancy, received a growth investment from Amulet Capital Partners. The deal amount was not disclosed. The company will use the funds to accelerate growth and expand strategic services for Medical, Clinical, and other critical path functions at the C-level of Life Sciences companies.PR NewswireAcquis Announces Investment in Venture Company, SSI Strategy, from Amulet Capital PartnersSSI Strategy, a Life Sciences consultancy, received a growth investment from Amulet Capital Partners. The investment will accelerate SSI's growth and expand strategic services for Medical, Clinical, and other critical path functions at the C-level of Life Sciences companies.